• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      The Swedish Council on Health Technology Assessment (SBU)
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [25419 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     National Institute for Health and Care Excellence (NICE) Sotatercept for treating pulmonary arterial hypertension. NICE technology appraisal guidance 1161
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [CR neuromodulation: Evidence report for the S3 guideline on chronic tinnitus]
2026     NIHR Health Services and Delivery Research programme Developing research resources and minimum data set for care homes’ adoption and use (DACHA)
2026     NIHR Health Technology Assessment programme Ethical implications of the use of AI-based technologies for medical image classification systems in screening: a qualitative systematic review
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [TMNMT: Evidence report for the S3 guideline on chronic tinnitus]
2026     NIHR Health Technology Assessment programme Laparoscopic hysterectomy versus open abdominal hysterectomy for women with a benign gynaecological condition: the LAVA RCT
2026     NIHR Health Technology Assessment programme Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimodal ES: Evidence report for the S3 guideline on chronic tinnitus]
2026     HTA South [Clinical benefit of photon-counting computed tomorgraphy - a systematic review and assessment of medical, economical, ethical and organisational aspects]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [VNS: Evidence report for the S3 guideline on chronic tinnitus]
2026     NIHR Health Services and Delivery Research programme Asymptomatic testing compared with standard care of the care home staff in shaping care home COVID-19 testing policy: the VIVALDI-CT pragmatic cluster RCT (VIVALDI-CT)
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) Cost-effectiveness evaluation of Nirmatrelvir/Ritonavir (Paxlovid)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Adhesions in the abdominal cavity: Do other measures help to relieve symptoms instead of surgery?]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [rTMS: Evidence report for the S3 guideline on chronic tinnitus]
2026     NIHR Health Technology Assessment programme Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis
2026     Ontario Health Preimplantation genetic testing for aneuploidy, monogenic disorders and structural rearrangements
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vulvodynia (itching and pain in the vulva area): What non-drug treatment options are promising?]
2026     NIHR Health Technology Assessment programme Magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn’s disease: the METRIC-EF multivariable prediction model, multicentre diagnostic inception cohort study
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of negative pressure wound therapy versus usual care for surgical wounds healing by secondary intention: the SWHSI 2 pragmatic RCT
2026     Ontario Health Ablative technologies for thyroid nodules
2026     NIHR Health Technology Assessment programme Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis
2026     NIHR Health Technology Assessment programme Artificial intelligence software to help detect fractures on X-rays in urgent care: an early value assessment
2026     Ontario Health Paclitaxel-coated balloon dilation for adults with recurrent bulbar urethral stricture
2026     NIHR Health Services and Delivery Research programme Utilisation of the support workforce in diagnostic imaging: a mixed-methods investigation
2026     NIHR Health Technology Assessment programme Duration of external neck stabilisation in the management of older and frail patients with a new odontoid fracture: the DENS RCT
2026     Ontario Health Hepatitis C screening
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2026     NIHR Health Technology Assessment programme Mapping components of behavioural weight management interventions using electronic survey and component selection by expert consensus: the BE:COME Study
2026     NIHR Health Technology Assessment programme Comparing the effectiveness, cost-effectiveness and implementation of low-dose oral modified release morphine in people with chronic breathlessness: a synopsis of a RCT and process evaluation
2026     Ontario Health Renal denervation for uncontrolled hypertension
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2026     NIHR Health Services and Delivery Research programme Ethnic differences in injury mortality rates among adult emergency healthcare service users in high-income countries: a scoping review
2026     Austrian Institute for Health Technology Assessment (AIHTA) Genetic testing in Austria - part A: application fields and prioritisation criteria
2026     HTA Region Stockholm [Interventions for preventing severe myopia in children: a systematic review of benefits and harms, cost-effectiveness, and cost analysis]
2026     Austrian Institute for Health Technology Assessment (AIHTA) Genetic testing in Austria. Part B: carrier screening for selected genetic conditions
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Characteristics of mental health outreach actions carried out for individuals or populations in situations of vulnerability]
2026     Austrian Institute for Health Technology Assessment (AIHTA) Genetic testing in Austria. Part C: detection of PIK3CA/AKT1/PTEN/ESR1 genetic alterations in HR+/HER2– breast cancer
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Frequent use of emergency departments by individuals with mental disorders]
2026     Austrian Institute for Health Technology Assessment (AIHTA) Combination therapy with antidepressants and vitamin B complex compared to antidepressant monotherapy – a systematic review
2026     Austrian Institute for Health Technology Assessment (AIHTA) Overview of national health economic evaluation guidelines: international best practices and implications for Austria
2026     Austrian Institute for Health Technology Assessment (AIHTA) Music therapy: clinical and socioeconomic outcomes and long-term measures in substance use disorder
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – serum protein electrophoresis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (mantle cell lymphoma)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cutaneous squamous cell carcinoma, CSCC)]
2026     Health Technology Wales (HTW) Rapid antigen detection tests for group A streptococcal infections to treat people with a sore throat in the community pharmacy setting
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [New surgical robotics platform for digestive oncology surgery]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria)]
2026     Health Information and Quality Authority (HIQA) Paediatric early warning system in emergency settings
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (complement 3 glomerulopathy)]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endoscopic stapler for distal pancreatectomy]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirmatrelvir/ritonavir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, >= 6 years to < 18 years, >= 20 kg)]
2026     Health Information and Quality Authority (HIQA) The management of acute asthma attack in adults
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (RET fusion-positive NSCLC, first line)]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Irreversible electroporation for treating colorectal cancer liver metastases]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nipocalimab (generalized myasthenia gravis)]
2026     Health Information and Quality Authority (HIQA) Protocol for the health technology assessment of the introduction of population-based screening for familial hypercholesterolaemia in children
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remimazolam (procedural sedation)]
2026     Belgian Health Care Knowledge Centre (KCE) Economic evaluation based on ‘PRECISe’, a randomised clinical trial funded by the KCE Trials programme (Study 2024-92)
2026     National Institute for Health and Care Excellence (NICE) Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. NICE technology appraisal guidance 1136
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remimazolam (general anaesthesia)]
2026     Belgian Health Care Knowledge Centre (KCE) Assessment of a mobile application in the rehabilitation of patients undergoing primary knee or hip arthroplasty (Study 2020-01)
2026     National Institute for Health and Care Excellence (NICE) Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). NICE technology appraisal guidance 1137
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis in children and adolescents)]
2026     National Institute for Health and Care Excellence (NICE) Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal). NICE technology appraisal guidance 1135
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Toripalimab (nasopharyngeal carcinoma)]
2026     National Institute for Health and Care Excellence (NICE) Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 1133
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Toripalimab (oesophageal carcinoma)]
2026     National Institute for Health and Care Excellence (NICE) Dupilumab for treating severe chronic rhinosinusitis with nasal polyps. NICE technology appraisal guidance 1134
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mirvetuximab soravtansine (ovarian cancer)
2026     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal). NICE technology appraisal guidance 1132
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years)]
2026     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1129
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Addendum to Project A25-128]
2026     National Institute for Health and Care Excellence (NICE) Obinutuzumab with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 1131
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teplizumab (type 1 diabetes mellitus, >= 8 years)
2026     National Institute for Health and Care Excellence (NICE) Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 1130
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotatercept (pulmonary arterial hypertension, WHO functional class IV)]
2026     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 1127
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gadopiclenol (contrast-enhanced magnetic resonance imaging, 0 to < 2 years)]
2026     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Nirmatrelvir plus ritonavir (Paxlovid)]
2026     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 1128
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirzepatide (type 2 diabetes mellitus in children and adolescents)]
2026     National Institute for Health and Care Excellence (NICE) Leadless cardiac pacemaker implantation for bradyarrhythmias. NICE HealthTech guidance 770
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Donidalorsen (hereditary angioedema)]
2026     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation. NICE HealthTech guidance 771
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colchicine (prophylaxis of ischaemic cardiovascular events after myocardial infarction)]
2026     National Institute for Health and Care Excellence (NICE) Pulmonary artery pressure technologies for remote monitoring of chronic heart failure. NICE HealthTech guidance 769
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment)]
2026     National Institute for Health and Care Excellence (NICE) Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. NICE highly specialised technologies guidance 34
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teprotumumab (thyroid eye disease)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (cholangiocarcinoma)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 4.0) and the statistical analysis plan (Version 4.0) – Fourth addendum to Project A22-83 (RPDC concept)]
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (COPD)]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (immunoglobulin G4-related disease)]
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (generalized myasthenia gravis)]